Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02834975
Recruitment Status : Recruiting
First Posted : July 15, 2016
Last Update Posted : July 13, 2021
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Marilyn Huang, MD, MS, University of Miami

Brief Summary:
The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and Pembrolizumab may result in deeper and more durable responses compared with standard chemotherapy alone.

Condition or disease Intervention/treatment Phase
Fallopian Tube Cancer Peritoneum Cancer Epithelial Ovarian Cancer Drug: Pembrolizumab Drug: Paclitaxel Drug: Carboplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy
Actual Study Start Date : December 22, 2016
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 1, 2022


Arm Intervention/treatment
Experimental: Pembrolizumab, Paclitaxel + Carboplatin

The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:

  • Pembrolizumab 200mg intravenously (IV);
  • Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);
  • Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);
  • Carboplatin IV area under the curve (AUC) of 6.
Drug: Pembrolizumab
Pembrolizumab on Day 1 of each cycle.
Other Names:
  • Keytruda
  • MK-3475

Drug: Paclitaxel
  • NACT: Paclitaxel on Day 1 of each cycle;
  • ACT: Paclitaxel same as NACT OR; dose-dense option weekly per protocol.
Other Name: Taxol

Drug: Carboplatin
Carboplatin IV on Day 1 of each cycle.




Primary Outcome Measures :
  1. Pathologic Objective Response Rate (pORR) in Participants Receiving Protocol Therapy [ Time Frame: up to 48 months ]
    Measure of pathologic response


Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) Rate in Participants Receiving Protocol Therapy [ Time Frame: Up to 48 months ]
    Rate of Progression-Free Survival (PFS) in participants receiving protocol therapy. PFS is defined as the length of time from the date of first dose of study treatment until date of disease progression or death due to any cause, whichever comes first.

  2. Rate of toxicity in participants [ Time Frame: Up to 48 Months ]
    Safety and tolerability of the intervention will be reported as the rate of toxicity in participants as assessed by treating physician



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. No prior treatment for primary advanced (Stage III or IV) high grade epithelial ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy, and/or other concurrent agents or therapies.
  2. Patients must undergo diagnostic laparoscopy for disease assessment for tissue biopsies to confirm diagnosis with planned interval tumor reductive surgery after completion of 3-4 cycles of treatment. For those not medically fit to undergo laparoscopy, as determined by the Investigator. (interventional radiology) IR-guided core biopsies may be used.
  3. Patients must be appropriate candidates for planned neoadjuvant chemotherapy with combination carboplatin and paclitaxel given intravenously (IV) every 3 weeks.
  4. Tissue from an archival sample or newly obtained core or excisional biopsy of a tumor lesion.
  5. Age ≥ 18 years.
  6. Life expectancy > 3 months.
  7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  8. Patients must have normal organ and marrow function as defined below:

    • Hematologic

      • Absolute neutrophil count (ANC) ≥1,500 /microliter (mcL).
      • Platelets ≥ 100,000 / mcL.
      • Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or Erythropoietin (EPO) dependency
    • Renal

      • Serum creatinine ≤ 1.5 X upper limit of normal (ULN) OR
      • Measured or calculated a creatinine clearance ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN (GFR can also be used in place of creatinine or CrCl). Creatinine clearance should be calculated per institutional standard.
    • Hepatic

      • Serum total bilirubin ≤ 1.5 X ULN OR
      • Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
      • Aspartate transaminase (AST/SGOT) and Alanine transaminase (ALT/SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases.
      • Albumin > 2.5 mg/dL
    • Coagulation

      • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
      • Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.
  9. Negative urine or serum pregnancy ≤ 72 hours (i.e. 3 days) prior to receiving the first dose of study medication if not surgically sterilized. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  10. Female subjects of childbearing potential (have not been surgically sterilized or have not been without menses for > 1 year) should be willing to use 2 methods of birth control at the same time or be surgically sterile, or abstain from heterosexual activity for the course of the study and at least 120 days after the last study dose.
  11. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients who are currently in or have participated in a study of an investigational agent or used an investigational device within 4 weeks of the first dose of treatment.
  2. Histology showing mucinous or low grade epithelial ovarian cancer.
  3. Patients who will not be likely to undergo interval tumor reductive surgery either secondary to performance status or sites of disease. If at the time of surgery, the patient is deemed to be surgically resectable to no gross residual, the patient will not be eligible for the study.
  4. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of Study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 28 days prior to Study treatment.
  5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  6. Has received prior therapy with an anti-PD1, anti-PDL1, anti-CD137, anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) or anti-PDL2 agent.
  7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  8. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  9. Prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents adverse events administered more than 4 weeks earlier.
  10. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to previously administered event.

    Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for this study. If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

  11. Has active autoimmune disease that has required systemic treatment in the past two years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  12. Evidence of interstitial lung disease or active, non-infectious pneumonitis
  13. Known psychiatric or substance abuse disorders that would interfere with cooperation with requirements of the study.
  14. Is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the pre-screening or screening visit through 120 days after the last dose of study treatment.
  15. Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  16. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  17. Received live vaccine within 30 days prior to the first dose of study treatment. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  18. Patient has active bacillus tuberculosis (TB).
  19. Patient with known hypersensitivity to pembrolizumab or any of its excipients.
  20. Patient receiving concurrent additional biologic therapy.
  21. History of allergic reactions attributed to compounds of similar chemical or biologic composition to carboplatin, paclitaxel not responsive to traditional desensitization procedures.
  22. Any other serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.
  23. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child who is an investigational site or sponsor staff directly involved with this trial, unless prospective institutional review board (IRB) approval (by chair or designee) is given, allowing exception to this criterion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02834975


Contacts
Layout table for location contacts
Contact: Marilyn Huang, MD, MS 305-243-2233 m.huang@med.miami.edu

Locations
Layout table for location information
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Marilyn Huang, MD, MS    305-243-2233    m.huang@med.miami.edu   
Principal Investigator: Marilyn Huang, MD, MS         
Sponsors and Collaborators
Marilyn Huang, MD, MS
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Marilyn Huang, MD, MS University of Miami
Layout table for additonal information
Responsible Party: Marilyn Huang, MD, MS, Associate Professor, University of Miami
ClinicalTrials.gov Identifier: NCT02834975    
Other Study ID Numbers: 20160477
First Posted: July 15, 2016    Key Record Dates
Last Update Posted: July 13, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Paclitaxel
Carboplatin
Pembrolizumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological